Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. is dated February 24, 2017. The report addresses Item 5.02 regarding the approval of 2016 annual bonuses for the Company's named executive officers by the Compensation Committee.
Key Financial Metrics
The filing does not provide company-wide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments for the fiscal years 2015 and 2016.
| Executive Officer | Role | 2016 Total Compensation | 2016 Bonus | 2015 Total Compensation |
|---|---|---|---|---|
| Hamza Suria, M.B.A. | President and CEO | $578,600 | $153,000 | $1,650,894 |
| Matthew Moyle, Ph.D. | Chief Scientific Officer | $877,927 | $44,405 | N/A (Joined May 2016) |
| Marco Londei, M.D. | Chief Medical Officer | $484,284 | $92,340 | $892,518 |
Material Changes Versus Prior Period
- Compensation Table Revision: The filing revises the 2016 Summary Compensation Table previously disclosed in the January 26, 2017 Prospectus. The prior table excluded 2016 bonuses as they were undetermined at the time of the IPO filing.
- 2016 vs. 2015 Compensation: Total compensation for Hamza Suria and Marco Londei decreased significantly in 2016 compared to 2015, primarily due to the absence of large option awards in 2016 that were granted in 2015.
- New Executive: Matthew Moyle's 2016 compensation reflects a partial year of employment starting May 16, 2016; no 2015 data is available for him.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business operations, or discussion of risks and contingencies. The document is strictly a disclosure of finalized executive bonus amounts.
Important Facts for Investor Verification
- Verify the impact of the revised 2016 compensation figures on the Company's total stock-based compensation expense and cash burn rate.
- Confirm the specific grant-date fair value assumptions used for the 2015 option awards, which drove the higher total compensation figures for 2015.
- Note that the 2016 bonus amounts were determined post-IPO and were not included in the initial prospectus filed in January 2017.